A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Akeso
- Target Recruit Count
- 60
- Registration Number
- NCT05319431
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳The First Hospital of Beijing University, Beijing, Beijing, China
🇨🇳Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
A Phase I Clinical Trial of AK115 in Healthy Subjects
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Akeso
- Target Recruit Count
- 42
- Registration Number
- NCT05286970
A Study to Evaluate the Efficacy and Safety of AK102 Q6W in Patients With Hyperlipidemia
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Akeso
- Target Recruit Count
- 240
- Registration Number
- NCT05260411
- Locations
- 🇨🇳
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Zhongshan Hospital, Fudan Hospital, Shanghai, China
A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Akeso
- Target Recruit Count
- 70
- Registration Number
- NCT05256472
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study to Evaluate the Efficacy and Safety of AK102 in Patients With Hyperlipidemia
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Akeso
- Target Recruit Count
- 450
- Registration Number
- NCT05255094
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
A Study to Evaluate the Long-term Efficacy and Safety of AK102 in Patients With Hyperlipidemia
- First Posted Date
- 2022-02-24
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Akeso
- Target Recruit Count
- 122
- Registration Number
- NCT05255458
- Locations
- 🇨🇳
The Third Hospital of Nanchang, Nanchang, Jiangxi, China
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
- Conditions
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2022-02-21
- Lead Sponsor
- Akeso
- Target Recruit Count
- 30
- Registration Number
- NCT05247684
A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Akeso
- Target Recruit Count
- 60
- Registration Number
- NCT05244642
- Locations
- 🇨🇳
Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, Guangdong, China
🇨🇳Xiangya Hospital Central South University, Changsha, Hunan, China
🇨🇳Qilu Hospital of Shandong University, Jinan, Shandong, China
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- Akeso
- Target Recruit Count
- 130
- Registration Number
- NCT05235542
- Locations
- 🇨🇳
Shanghai Renji Hospital, Shanghai, China
A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Akeso
- Target Recruit Count
- 636
- Registration Number
- NCT05235516
- Locations
- 🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳Guizhou Cancer Hospital, Guiyang, Guizhou, China